Progenics Pharmaceuticals (PGNX): Price Target and June Short Interest Disclosure

Progenics Pharmaceuticals (PGNX) : The most positive equity analysts on Progenics Pharmaceuticals (PGNX) expects the shares to touch $14, whereas, the least positive believes that the stock will trade at $9 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $11.5 with an expected fluctuation of $3.54 from the mean.

Progenics Pharmaceuticals (PGNX) encountered a drop of 0.1% or -5,209 shares in the short positions. The number dropped from 8,448,569 on June 15,2016 to 8,443,360 on June 30,2016. The final interest is 12.3% of the floated stock. The days to cover figure of 9 can be arrived using the average daily exchange of 891,148 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.


Progenics Pharmaceuticals (NASDAQ:PGNX): On Thursdays trading session , Opening price of the stock was $5.04 with an intraday high of $5.17. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.82. However, the stock managed to close at $4.83, a loss of 1.83% for the day. On the previous day, the stock had closed at $4.92. The total traded volume of the day was 2,250,814 shares.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.